GENESIS:基因型指导 - 利钠肽 - 心脏代谢健康研究
心钠素与心脏代谢健康的调节:基因型引导的人体生理学研究
Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have ~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have ~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.
研究概览
地位
详细说明
The heart plays an endocrine role by secreting hormones called Natriuretic Peptides (NPs). NPs directly regulates blood pressure (BP) by causing dilation of blood vessels and removing sodium and water from the body. Apart from blood pressure regulation, previous experimental data suggest that NPs has a wide range of favorable metabolic effects and regulates energy homeostasis, fatty acid oxidation, lipid metabolism, glucose intolerance, insulin sensitivity, and obesity. Investigators have demonstrated that low levels of NPs can increase the risk of developing cardiovascular (CV) events (such as heart failure [HF], stroke, myocardial infarction [MI], or heart attack).
Former studies by the investigators have shown that the NP deficient states such as obese and black individuals contributes to lower energy expenditure, poor metabolic profile and promotes the onset of diabetes. Certain genetic factors contribute to the higher predisposition to cardiometabolic disease in individuals with relative atrial natriuretic peptide (ANP) deficiency. PI and others have identified a common genetic variant, rs5068 is associated with higher plasma ANP levels.
The lack of the rs5068 variant has a comparable effect on ANP levels as seen in obese and black individuals and plays a causal role in cardiometabolic health regulation. The rs5068 variant is only present in 10-12% of the population, thereby leaving nearly 90% of adults vulnerable to the potential adverse cardiometabolic impact of having a relative ANP deficiency. This indicates that a low ANP genotype is associated with a poor metabolic health profile.
Our earlier study, in normotensive healthy young adults, demonstrated that a high glucose meal results in reduce ANP levels by 20-30%, which indicates that ANP is a glucose-responsive hormone. The preliminary data from our ongoing clinical trial has shown increased ANP levels with response to the exercise. The impact of genetically determined low ANP levels on the differences in exercise-induced ANP (beneficial) increase and glucose load-induced suppression of ANP (detrimental) is not known in humans.
Micro-RNA-425 (miR-425) is a negative regulator of ANP and acts in a genotype-specific manner. In our previous study, the investigators have demonstrated that miR-425 levels decreased by 71% following one week on a high-salt diet compared with a low-salt diet in individuals with low ANP genotype, and no change was seen in high ANP genotype individuals. In vitro experiments in animals showed an increase in cardiac miR-425 levels by 22-30%. The negative regulator of ANP also independently negatively regulates the control of energy expenditure. The responsiveness of mir-425 to glucose challenge and exercise challenge (metabolic perturbations) has not been previously evaluated in humans.
Individuals with genetically reduced amounts of ANP will be the focus of our present genotype-guided physiological investigation. Following the glucose and exercise challenges, the investigators will additionally investigate the extent to which miR-425 mediated control of ANP suppression occurs. This study will help in understanding how ANP regulates cardiometabolic health in individuals with genetically lower ANP levels.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Nehal Vekariya, MS
- 电话号码:205-934-7173
- 邮箱:nvekariya@uabmc.edu
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- 招聘中
- University of Alabama at Birmingham
-
首席研究员:
- Pankaj Arora, MD
-
接触:
- Nehal Vekariya, MS
- 电话号码:205-934-7173
- 邮箱:nvekariya@uabmc.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults: Age more than or equal to 18; an equal number of Males and Females
- Consent to the collection of genetic material
- Willing to adhere to the study protocol
Exclusion Criteria:
- Age <18, at screening.
- BMI >45 kg/m2.
- Blood pressure more than 140/90 mmHg.
- Participants who are taking more than 2 hypertension medications.
- History of diabetes or fasting plasma glucose >126 mg/dl or HbA1C>=6.5% or prior treatment with antidiabetic medication.
- Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)
- Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence);
- Estimated GFR < 60 ml/min/1.73 m2; albumin creatinine ratio ≥30 mg/g
- Hepatic Transaminase (AST and ALT) levels >3x the upper limit of normal
- Anemia (men, Hct < 38%; women, Hct <36%)
- Inability to exercise on a treadmill
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental: Low NP Genotype Group
150 healthy adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours. |
Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB) Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass. Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test. Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours. |
|
实验性的:Active Comparator: High NP Genotype Group
50 healthy adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours. |
Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB) Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass. Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test. Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
高基因型组和低基因型组之间标准化口服葡萄糖攻击后 MRproANP 水平的变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
高基因型和低基因型组之间运动能量消耗的变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
在具有低 ANP 基因型的人群中进行标准化口服葡萄糖挑战后 miR-425 水平的变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
在具有低 ANP 基因型的人群中进行标准化运动挑战后 miR-425 水平的变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
高基因型组和低基因型组之间葡萄糖攻击后 NP(ANP、BNP、NTproBNP)的变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
高基因型组和低基因型组之间葡萄糖攻击后血糖的变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
高基因型组和低基因型组之间葡萄糖攻击后血清胰岛素的变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
两个基因型组之间静息能量消耗 (REE) 的变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
NP(ANP、BNP、NTproBNP)的变化与两个基因型组之间的标准化运动方案。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
两个基因型组之间标准化运动方案的血糖水平变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
两个基因型组之间标准化运动方案的血清胰岛素水平变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
两个基因型组之间标准化运动方案的游离脂肪酸水平变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
两个基因型组之间标准化运动方案的甘油水平变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
葡萄糖激发后 miR-425 水平随着 NP 水平(ANP、MRproANP、BNP 和 NTproBNP)的变化而变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
运动挑战后 miR-425 水平随着 NP 水平(ANP、MRproANP、BNP 和 NTproBNP)的变化而变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
葡萄糖挑战后 miR-425 水平随血清葡萄糖水平的变化而变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
MiR-425 水平随葡萄糖挑战后血清胰岛素水平的变化而变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
运动挑战后 miR-425 水平随血清葡萄糖水平的变化而变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
MiR-425 水平随运动挑战后血清胰岛素水平的变化而变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
在两个基因型组之间进行葡萄糖攻击后,miR-425 水平随着 NP 水平(ANP、MRproANP、BNP 和 NTproBNP)的变化而变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
在两个基因型组之间进行运动挑战后,miR-425 水平随着 NP 水平(ANP、MRproANP、BNP 和 NTproBNP)的变化而变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
两个基因型组之间葡萄糖攻击后 miR-425 水平随血清葡萄糖水平的变化而变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
两个基因型组之间葡萄糖攻击后 miR-425 水平随血清胰岛素水平的变化而变化。
大体时间:食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
食用研究餐 5 天后,主要研究访问日的第 1 小时至第 8 小时
|
|
|
两个基因型组之间运动挑战后 miR-425 水平随血清葡萄糖水平的变化而变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
两个基因型组之间运动挑战后 miR-425 水平随血清胰岛素水平的变化而变化。
大体时间:食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
食用研究餐 4 天后,在锻炼挑战访问日约 3 小时
|
|
|
Correlation of resting miR-425 levels with REE
大体时间:About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
|
Levels of miR-425 measured in 2-ΔΔCT will be assessed and will be related to REE measured in kcal/min |
About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
|
|
Correlation of resting miR-425 levels with REE between the genotype groups.
大体时间:About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
|
Levels of miR-425 levels measured in 2-ΔΔCT will be related to the REE measured in kcal/min and will be compared between the genotype groups |
About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
|
合作者和调查者
调查人员
- 首席研究员:Pankaj Arora, MD, FAHA、University of Alabama at Birmingham
出版物和有用的链接
一般刊物
- Parcha V, Patel N, Gutierrez OM, Li P, Gamble KL, Musunuru K, Margulies KB, Cappola TP, Wang TJ, Arora G, Arora P. Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals. J Am Coll Cardiol. 2021 May 11;77(18):2291-2303. doi: 10.1016/j.jacc.2021.03.291.
- Arora P, Wu C, Hamid T, Arora G, Agha O, Allen K, Tainsh RET, Hu D, Ryan RA, Domian IJ, Buys ES, Bloch DB, Prabhu SD, Bloch KD, Newton-Cheh C, Wang TJ. Acute Metabolic Influences on the Natriuretic Peptide System in Humans. J Am Coll Cardiol. 2016 Feb 23;67(7):804-812. doi: 10.1016/j.jacc.2015.11.049.
- Bajaj NS, Gutierrez OM, Arora G, Judd SE, Patel N, Bennett A, Prabhu SD, Howard G, Howard VJ, Cushman M, Arora P. Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. JAMA Cardiol. 2018 Jan 1;3(1):11-17. doi: 10.1001/jamacardio.2017.4207.
- Arora P, Reingold J, Baggish A, Guanaga DP, Wu C, Ghorbani A, Song Y, Chen-Tournaux A, Khan AM, Tainsh LT, Buys ES, Williams JS, Heublein DM, Burnett JC, Semigran MJ, Bloch KD, Scherrer-Crosbie M, Newton-Cheh C, Kaplan LM, Wang TJ. Weight loss, saline loading, and the natriuretic peptide system. J Am Heart Assoc. 2015 Jan 16;4(1):e001265. doi: 10.1161/JAHA.114.001265.
- Parcha V, Kalra R, Li P, Oparil S, Arora G, Arora P. Nocturnal blood pressure dipping in treated hypertensives: insights from the SPRINT trial. Eur J Prev Cardiol. 2022 Feb 19;29(1):e25-e28. doi: 10.1093/eurjpc/zwaa125. No abstract available.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.